Alle Personen

Prof. Dr. Stephan Becker

Marburg/ DE

University Marburg

Weitere Beteiligungen

  • –   
    • Short Talk
    • S-2-3
    MVA-MERS-S vaccine candidate elicits long-lasting memory B cell response and highly potent cross-neutralizing antibodies against zoonotic merbecoviruses
     Immune Prevention and Therapy
    • Poster
    • P-1-38
    A combination of direct acting and host-directed antivirals dramatically suppresses SARS-CoV-2 and MERS-CoV replication
     Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
    • Poster
    • P-1-39
    Brain specific immune responses to Nipah- and Ebola virus infection in in-vitro and ex-vivo models
     Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
    • Poster
    • P-1-40
    Establishment and characterization of lethal and non-lethal animal models for Marburg virus
     Susceptibility to Infectious Diseases: Challenges and Ways Towards New Solutions
    • Poster
    • P-2-55
    Generation and in vitro characterization of two recombinant MVA candidate vaccines expressing Marburg virus glycoprotein or nucleoprotein
     Tropical and Emerging Infections
    • Poster
    • P-2-62
    Corallopyronin A: successful non-GLP in vivo toxicity tests in rat and dog support continued development to first in human trials
     Tropical and Emerging Infections
    • Poster
    • P-2-66
    Establishment and characterization of two Crimean-Congo hemorrhagic fever virus animal models in mice
     Tropical and Emerging Infections
    • Poster
    • P-2-88
    The Antiviral Compound Testing Platform (ACTP) and its application to identify broad-spectrum antivirals
     Tropical and Emerging Infections
    • Poster
    • P-2-98
    Development of a physiologically based biopharmaceutics model for CorA and prediction of human pharmacokinetics and effective dose using enhanced formulation
     Tropical and Emerging Infections
    • Poster
    • P-2-101
    Diagnostic qRT-PCR as screening assays of antiviral compounds against highly pathogenic RNA viruses
     Tropical and Emerging Infections
    • Poster
    • P-2-105
    MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike induce differential S1- and S2-specific immune responses in humans
     Tropical and Emerging Infections
    • Poster
    • P-1-78
    Dissecting humoral immune responses to the MVA-MERS-S vaccine candidate using a systems serology approach
     Immune Prevention and Therapy
  • –   
    • Short Talk
    • S-6-4
    The vaccine candidate MVA-MERS-S against Middle East Respiratory Syndrome Coronavirus: safety and immunogenicity results from a randomized-controlled Phase Ib trial
     Tropical and Emerging Infections
  • © Conventus Congressmanagement & Marketing GmbH